8-K: Walgreens Boots Alliance Lowers Fiscal 2024 Guidance Amidst Challenging Market Conditions

Walgreens Boots Alliance has lowered its fiscal year 2024 adjusted EPS guidance due to a difficult operating environment and persistent pressures on the U.S. consumer.

Summary

• Walgreens Boots Alliance (WBA) reported its fiscal 2024 third quarter results, which ended May 31, 2024.
• Third quarter sales increased by 2.6% year-over-year to $36.4 billion, or 2.5% on a constant currency basis.
• Reported earnings per share (EPS) was $0.40, compared to $0.14 in the same quarter last year, which included a non-cash impairment of pharmacy license intangible assets in Boots UK.
• Adjusted EPS was $0.63, a 36.6% decrease on a constant currency basis, impacted by lower sale-leaseback gains, a challenging U.S. retail environment, and pharmacy industry trends.
• The company has lowered its fiscal 2024 adjusted EPS guidance to $2.80 to $2.95, reflecting these challenges.
• WBA is finalizing a multiyear footprint optimization program to close underperforming U.S. stores.
• They are also launching a U.S. Retail Pharmacy action plan to improve customer and patient experience.
• The company is aligning its U.S. Pharmacy and Healthcare organizations and simplifying its U.S. Healthcare portfolio.
• Net cash provided by operating activities was $605 million in the third quarter, and free cash flow was $334 million, a $778 million increase compared to the prior year, driven by working capital optimization and decreased capital expenditures.
• Year-to-date sales increased 6.2% to $110.1 billion, or 5.6% on a constant currency basis.
• The company reported a net loss of $5.6 billion for the first nine months of fiscal 2024, which includes a $12.4 billion non-cash impairment charge related to VillageMD goodwill.
• Adjusted net earnings decreased 24.9% to $2.2 billion for the first nine months of fiscal 2024.
• The U.S. Retail Pharmacy segment saw a 2.3% increase in sales to $28.5 billion, driven by comparable pharmacy sales, but retail sales declined by 4.0%.

Sentiment

Score: 3

Explanation: The document conveys a negative sentiment due to lowered guidance, significant losses, and a challenging operating environment. While there are some positive aspects, the overall tone is one of concern and the need for a turnaround.

Positives

• Third quarter sales increased by 2.6% year-over-year.
• Free cash flow improved significantly by $778 million compared to the prior year quarter.
• The U.S. Healthcare segment showed improvement with positive adjusted EBITDA for the second consecutive quarter.
• Boots UK comparable retail sales increased 6.0% and total retail market share increased.
• Boots.com sales grew 13.8%, representing 15.6% of Boots total retail sales.

Negatives

• Adjusted EPS decreased by 36.6% on a constant currency basis.
• Fiscal 2024 adjusted EPS guidance was lowered to $2.80 to $2.95.
• The company reported a net loss of $5.6 billion for the first nine months of fiscal 2024.
• The U.S. Retail Pharmacy segment experienced a 4.0% decline in retail sales.
• Adjusted operating income decreased 36.3% on a constant currency basis.
• The company is closing underperforming U.S. stores as part of a footprint optimization program.

Risks

• The company faces a difficult operating environment, including persistent pressures on the U.S. consumer.
• Recent marketplace dynamics have eroded pharmacy margins.
• The U.S. retail environment remains challenging.
• Reimbursement pressure is impacting pharmacy margins.
• The company is experiencing higher shrink levels in retail.
• The company is facing a $12.4 billion non-cash impairment charge related to VillageMD goodwill.

Future Outlook

The company has lowered its fiscal 2024 adjusted EPS guidance to $2.80 to $2.95, reflecting a challenging operating environment and persistent pressures on the U.S. consumer. They are focused on improving their core business, retail pharmacy, and are addressing critical issues with urgency.

Management Comments

• We continue to face a difficult operating environment, including persistent pressures on the U.S. consumer and the impact of recent marketplace dynamics which have eroded pharmacy margins.
• Our results and outlook reflect these headwinds, despite solid performance in both our International and U.S. Healthcare segments.
• Informed by our strategic review, we are focused on improving our core business: retail pharmacy, which is central to the future of healthcare.
• We are addressing critical issues with urgency and working to unlock opportunities for growth.
• Many of these actions will take time, but I am confident that we have the right team and the right strategy to lead a business turnaround for the Walgreens that our customers and patients need.

Industry Context

The announcement reflects broader challenges in the retail pharmacy industry, including reimbursement pressures and changing consumer behavior. The company's strategic review and focus on core business areas indicate an attempt to adapt to these industry trends.

Comparison to Industry Standards

• Walgreens' adjusted EPS decline of 36.6% is significantly worse than CVS Health's recent results, which saw a more modest decline in adjusted EPS.
• The $12.4 billion goodwill impairment charge related to VillageMD is a substantial write-down, indicating potential overvaluation of the acquisition, which is not typical for industry leaders.
• While other pharmacy chains are also facing reimbursement pressures, Walgreens' retail sales decline of 4.0% is more pronounced than some of its competitors.
• The strategic review and store closures are similar to actions taken by other retailers facing overcapacity, but the scale of Walgreens' optimization program suggests a more significant need for restructuring.
• Boots UK's strong performance, particularly in online sales, is a positive contrast to the challenges in the U.S. market, highlighting the importance of international diversification.

Stakeholder Impact

• Shareholders will be negatively impacted by the lowered guidance and significant losses.
• Employees may be affected by the store closures and restructuring efforts.
• Customers may experience changes in store locations and services.
• Suppliers may be impacted by the company's cost-cutting measures.

Next Steps

• Finalizing a multiyear footprint optimization program to close underperforming U.S. stores.
• Launching a U.S. Retail Pharmacy action plan to improve customer and patient experience.
• Aligning U.S. Pharmacy and Healthcare organizations for enhanced go-to-market capabilities.
• Simplifying and focusing the U.S. Healthcare portfolio.

Key Dates

Keywords

Walgreens Boots Alliance, WBA, pharmacy, retail, healthcare, EPS, sales, guidance, operating income, footprint optimization, VillageMD, Boots UK